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Cumulative reduction in breast cancer mortality has been shown in
a number of controlled mammographic screening studies (Shapiro
et al, 1988; Fletcher et al, 1993; Nystrom et al, 1993; Gordis et al,
1997). Such reductions for women 50–69 years of age at screening
have been observed to be about 30% 10–12 years after study entry,
and for this age-group mammographic screening is today an
accepted method. For women 40–49 years of age, however, most
of the individual trials have so far not demonstrated statistically
convincing evidence of reduction in breast cancer mortality, and
the beneficial effect of breast cancer screening is still under
debate. However, recent results from the Gothenburg and Malmö
studies are indicating a statistically significant reduction of about
40% (95% confidence interval 5–70%) (Andersson and Janzon,
1997; Bjurstam et al, 1997).
Among adverse effects that should be taken into account is the
risk for radiation-induced breast cancer, especially for women in
the lower age group. In most published epidemiological studies
this risk has been found to be higher for women < 50 years of age
compared to women ³ 50 years of age at time of exposure
(UNSCEAR, 1988). For a given age at exposure the excess
relative risk estimates per Gy found in the various studies differ
within a factor of four (Mattsson et al, 1995).
The balance between benefit and risk is crucial for the outcome
of a screening programme. In this paper we calculate measures of
efficiency under varying assumptions for the reduction in breast
cancer mortality and for the risk of radiation-induced breast cancer
respectively. The calculations cover a long period of time because
radiation-induced breast cancer deaths can occur after a relatively
long latency. The main purpose of this study was to evaluate the
effect of a mammographic screening programme on breast cancer
incidence and mortality as well as the associated years of life
gained or lost. This was achieved by following a hypothetical
cohort of 40-year-old women throughout life.
MATERIALS AND METHODS
In different breast cancer screening trials the reduction in breast
cancer mortality has been expressed in relative terms, which
means that the higher the background breast cancer mortality, the
higher the number of years of life gained for a given reduction.
Breast cancer mortality is lower in Sweden compared to some
other Western societies, such as The Netherlands, the UK or the
US (Bjurstam et al, 1997). In this study we have chosen popula-
tion-based data from the female population of Stockholm to
calculate the effects on years of life. Compared to women in the
UK these women have similar breast cancer incidence rates
(IARC, 1992), but around 20% lower breast cancer mortality rates
(Berrino et al, 1995; Stockholm Breast Cancer Study Group,
1997).
Measures of effect were related to background breast cancer
mortality rates (i.e. rates that would persist if screening was not
present) and based on a cohort of 100 000 40-year-old women
with no history of breast cancer being followed until 100 years of
age. During the follow-up, the size of the cohort decreased by
death risks specific to the attained age. For details of calculations
see Appendix.
Background breast cancer mortality
The background breast cancer mortality was calculated using
number of breast cancers diagnosed per year of age, cumulative
survival rates and annual death rates. Incidence data were obtained
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from the Regional Cancer Register of the Stockholm County for
period of diagnosis 1977–1986 (Figure 1). Survival and death rates
for the first 20 years after diagnosis were obtained from patients
diagnosed during 1970–1979, and the rates 20–29 years after
diagnosis from patients diagnosed during 1961–1969. These data
were thus from 1970–1988. This period was chosen to minimize
the influence of mammographic screening programmes on back-
ground breast cancer mortality rates and to be as current as
possible. Mammographic screening programmes were introduced
in the Stockholm region in 1989.
The survival rates were confined to breast cancer deaths only
and calculated using data from the Swedish Cause of Death
Register for the patients registered in the Stockholm–Gotland
Regional Cancer Register. No breast cancer death was reported
among these patients more than 20 years after the initial diagnosis.
The rates are shown graphically in Figure 2. The calculated breast
cancer mortality rates are shown in Figure 1.
Effects of mammographic screening
Reduction in background breast cancer mortality
The effect of screening was calculated assuming a reduction of the
background rate, i.e. of the breast cancer mortality generated
among breast cancer patients diagnosed during selected ages with
mammographic screening. Numerical values for the reduction are
available from the overview of the Swedish randomized mammo-
graphy screening trials (Nystrom et al, 1993; Tabar et al, 1996). In
these trials, the effect was not seen until a certain time period after
the first screening round. For women 40–49 years of age at
screening, this lag-period was 7 years and for women between
50 and 69 years of age it was 3 years (Nystrom et al, 1993).
For the time after the lag-period we assumed a constant annual
reduction of the breast cancer mortality (‘P’ in Appendix). This
might be a too large simplification, but is not unrealistic given the
Swedish overview results (Nystrom et al, 1993). For ages between
40 and 49 years at screening we made calculations for an annual
breast cancer mortality reduction in the range 10–45%. This range
corresponds to a cumulative reduction of 7–25% 10 years after
screening start (given no screening after 50 years of age; Figure 3).
In the overview of the Swedish randomized trials, the cumulative
reduction was 13% after a median follow-up of 9 years. The
attendance rate was »80% (Nystrom et al, 1993). In a recent
update the cumulative reduction was reported to 23% after a
median follow-up of 13 years (Tabar et al, 1996). In the 11-year
follow-up of the Gothenburg breast screening trial a 45% cumula-
tive reduction was observed (Andersson and Janzon, 1997).
However, due to the design of these studies, it is difficult to
quantify the part of the cumulative reduction that relates to
screening before 50 years of age (Gordis et al, 1997).
For the ages at screening between 50 and 69 years, we used an
annual reduction of 30%. This corresponds to a cumulative reduc-
tion of approximately 29% after 12 years, which thus reflects the
results of the Swedish overview (Nystrom et al, 1993). For
comparative purposes analyses were also done using a 20% and a
40% annual reduction respectively. When appropriate, the annual
reductions are referred to as ‘x% reductions’.
The mean lead time introduced by screening has been estimated
at 3 years (Rimer, 1996), which implies that the breast cancer
incidence is lower than the background after a screening
programme is stopped. We assumed the incidence to increase by
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Figure 1 Age-specific breast cancer incidence rate of first primary tumours
per 100 000 women in Stockholm county during 1977–1986 and calculated
age-specific breast cancer mortality rates  
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Figure 2 Survival rates for women aged <50 years, 50–69 years, and >69
years at diagnosis of breast cancer in Stockholm county. For details see text
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one-third of this difference per year after the screening has come to
an end so that the background level is reached 3 years later.
Induced breast cancer cases
When calculating the number of radiation-induced breast cancers
due to a given mammographic screening programme involving a
certain radiation dose, four factors are of importance: the excess
relative risk (ERR) of breast cancer caused by ionizing radiation;
the latency time for the excess to emerge; the background breast
cancer incidence; and the decrease by attained age (time) of the
size of the screened population.
Breast cancer risk. Results for women exposed to low doses are
not available; in fact, it would be impossible to come to conclusive
results with doses present in screening programmes (dose to the
breast less than a few hundred mGy) even with hundreds of
thousand of women in a study (Land, 1980). So, estimates of
breast cancer risks from low-dose radiation exposures must be
based on information obtained from studying populations exposed
to much higher doses. Extrapolations to low doses are usually
based on the use of theoretical and experimental radiobiological
target theories, where the risk increases linearly at low doses with
an upward curvature at medium dose levels (UNSCEAR, 1993).
We considered the results from the four most informative breast
cancer risk studies, i.e. the A-bomb survivors study (Tokunaga et
al, 1994), the Massachusetts fluoroscopy study (Boice et al, 1991),
the New York mastitis study (Shore et al, 1986) and the benign
breast disease study (Mattsson et al, 1995). In accord with these
studies we assumed a linear increase in ERR with dose yet modi-
fied by age-at-exposure. (The higher age-at-exposure the lower
ERR Gy–1.) The excess incidence by attained age was taken rela-
tively to the background incidence rates. We also assumed the
excess risk to remain elevated throughout life (UNSCEAR, 1994).
However, risk gradients differ between the studies. Because we
cannot determine which is the most relevant we made calculations
both with a high-risk and with a low-risk alternative. The high-risk
alternative chosen was the ERR observed for women irradiated for
benign breast disease (Mattsson et al, 1995) and the low-risk
alternative chosen was from women with lung tuberculosis who
received lung collapse therapy and who underwent fluoroscopy in
Massachusetts (Boice et al, 1991). Formulas for the dose–response
models are given in the Appendix.
Latency. We used a graded impact of the ERR that increases to
full impact 10 years after exposure according to figures published
by the National Institute of Health (NIH, 1985) (see Appendix).
Background rates. The same incidence rates as for the
calculation of background mortality were used (Figure 1). These
rates are not influenced by mammographic screening programmes
introduced later.
Size of population. The hypothetical screening population
decreased in size by death risks on a year by year basis. Data were
obtained from the female population of Stockholm during
1980–1989 (Institute of Regional Analyses in Stockholm,
INREGIA). Because women diagnosed with breast cancer and still
alive are not invited to service screening, they too were excluded,
year by year, from the hypothetical screening population.
Induced breast cancer deaths
The number of induced breast cancer deaths was calculated in
analogy to the calculation of the background breast cancer deaths.
The number of registered breast cancers was replaced by the calcu-
lated number of induced breast cancers. The effect of the screening
programme due to the reduction in breast cancer mortality on the
number of induced deaths was calculated in the same way as for
the number of breast cancer deaths described above and in the
Appendix.
Net effects
The net number of avoided breast cancer deaths was calculated as
the difference between the background breast cancer mortality and
the breast cancer mortality with mammography (with the induced
breast cancer mortality taken into account) with summation from
the starting age for the hypothetical cohort (i.e. 40 years) up to 100
years of age. In calculating the years of life gained (or lost), life
table data for women in Stockholm county during the period
1986–1990 were used (INREGIA).
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RESULTS
Screening of women from 40 to 49 years of age
The number of years of life gained and lost and the number of
deaths avoided and induced for our cohort of 100 000 women is
shown in Figures 4 and 5 respectively. R10%, …, R40% denote a
10%, …, 40% reduction in breast cancer mortality respectively.
‘Higher-RR’ correspond to the radiation risk observed in the
benign breast disease study (Mattsson et al, 1995). The effect is
slightly dependent on the magnitude of the reduction of breast
cancer mortality, which is indicated in the Figure. The dotted line
is the result for a 20% reduction in breast cancer mortality, and the
band around the dotted line represents the range between 40%
and 0%. ‘Lower-RR’ corresponds to the risk observed in the
Massachusetts fluoroscopy study (Boice et al, 1991).
The total number of years of life gained associated per
percentage unit in reduction of breast cancer mortality was
approximately 130 years. The number of years of life lost was
around 5 per mGy for the lower and around 24 per mGy for the
higher radiation risk assumption.
The dose for which the number of induced breast cancer deaths
becomes equal to the number of avoided breast cancer deaths is
lower than that for the correspondent comparison for the number
of years of life (Figures 4 and 5). The reason is that, on average,
radiation-induced breast cancer deaths occur later than the avoided
breast cancer deaths would have had.
In the specific scenario for 40–49 years of age we assumed the
screening interval to be 18 months as recommended by the health
authority. Dose values from routine mammography in Sweden
1994 were used (W Leitz, unpublished data). Per screening round,
1.5 views were taken on average with a mean absorbed dose of
1.5 mGy per view. Assuming an attendance rate of 80%, a recall
rate of 5% and three views at recall examination gives a total
absorbed dose for the programme of »13 mGy per invited woman.
The annual reduction in breast cancer mortality associated with the
screening programme was assumed to be 25% from 7 years after
first mammographic screen and remaining throughout life. The
corresponding cumulative reduction is given in Figure 3.
The lifetime cumulative risk of breast cancer for such a
programme increased from 9.29% to 9.30% or 9.35% with the
lower and higher radiation risk assumption respectively (Table 1).
The net number of years of life gained was between 2800 and 3100
(Table 1).
Delaying the screening start in steps of 1 year, from 40 to 41, 42,
…, 49 years of age (and assuming a 25% annual breast cancer
mortality reduction) gradually decreased the number of net gained
years from a maximum of 3100 to 1200. The ratio between
avoided and induced deaths increased from 5 to 21 for the higher
radiation risk alternative and from 26 to 128 for the lower radia-
tion risk assumption respectively. The ratio between gained and
lost years was approximately 2 times higher.
For routine mammographic screening in Sweden 1994 the 90th
percentile of the absorbed breast dose distribution was observed to
1.9 mGy per view and the corresponding number of views per
examination to two (W Leitz, unpublished data). For these values
(for screening interval of 18 months and 25% reduction in breast
cancer mortality) net years gained were (with figures for the
higher radiation risk assumption presented first) 2600:3100 (ratio
avoided/induced deaths: 2.8: 12.7). Using the most extreme mean
absorbed breast dose reported for mammographic screening in
Sweden 1994 (3.2 mGy per view) reduced the net years gained to
2300: 3000 (ratio avoided/induced deaths: 1.7:7.6).
Screening of women from 40 to 69 years of age
The same assumptions as in the first scenario (i.e. for 40- to 49-
year-old women) were used. For the ages 50–69 years, we
assumed that 1.5 views were taken (1.5 mGy per view) every
second year from 50 years of age. Participation rate was 80% and
recall rate 3% with three views at 1.5 mGy. The 2-year screening
interval represents the mean interval for the Swedish randomized
trials (Nystrom et al, 1993). The total cumulative absorbed dose
for the programme was »33 mGy per invited woman.
We used a 30% annual reduction in breast cancer mortality for
ages at screening of 50–69 years. Such an annual reduction would
give a cumulative reduction 15 years from start of screening of
»28%, in a population of 50-year-old women with no previous
diagnosis of breast cancer. The cumulative figure is lower than the
annual figure due to the 3-year lag-time for the screening benefit
that was assumed. However, for our scenario with screening from
40 to 69 years of age the assumption of a 3-year lag-time from 50
to 52 years of age was changed from no effect to the same effect as
used for the 40- to 49-year age-group.
Figure 6 shows the cumulative reduction of breast cancer
mortality for different annual breast cancer mortality reductions as
a consequence of screening at ages 40–49 years, and a given
reduction of 30% of screening at ages 50–69 years.
Table 1 Breast cancer incidence and mortality without and after
mammographic screening of a hypothetical cohort of 100 000 women aged
40 years followed to 100 years of age1
Screening between
40–49 years of age 40–69 years of age
Radiation risk
Higher2 Lower3 Higher2 Lower3
Cumulative incidence
No mammography, % 9.29 9.29 9.29 9.29
+ radiation-induced
cases, % 9.35 9.30 9.37 9.31
No. of induced cases 53 12 76 16
Cumulative mortality
No mammography, % 4.05 4.05 4.05 4.05
With mammography4, % 3.96 3.94 3.40 3.38
Percentage reduction 2.1 2.6 15.9 16.5
No. of avoided deaths 111 111 674 674
No. of induced deaths 24 5 31 7
Avoided/induced deaths 5 21 22 104
No. of gained years 3170 3170 13 500 13 500
No. of lost years 325 71 357 75
Avoided/induced years 10 45 38 180
1Two programmes were compared: a. Screening from 40 to 49 years of age
with in average 1.5 views at 1.5 mGy per examination every 18 months (total
dose/woman »13 mGy). b. Same as 1: + biannual examinations 1.5 views at
1.5 mGy from 50 to 69 years of age (total dose/woman »33 mGy).
Attendance rate 80%. Recall rate: 5% for <50 years of age; 3% for ³50 years
of age. Three views at recall examination. 2ERR estimated for women in the
benign breast disease study (Mattsson et al, 1995). 3ERR estimated for
women in the Massachusetts fluoroscopy study (Boice et al, 1991). 4Annual
reduction in breast cancer mortality was 25% beginning 7 years after first
examination for the 40- to 49-year age-group. For the 50- to 69-year
age-group a 30% annual reduction was used. The reduction assumed to stay
throughout life.The 30% breast cancer mortality reduction associated with
screening at ages 50–69 years resulted in a net gain of approxi-
mately 9900 years of life, independently of radiation risk assump-
tion. Varying the assumption of the reduction figure by 10%
changed the net gain of years by approximately 3300.
The additional numbers of gained years as a consequence of
screening the 40- to 49-year age-group was 140 per percentage
unit change in breast cancer mortality reduction given the 30%
reduction for the older age group (Figure 7).
A 25% reduction for the 40 to 49 (i.e. 40–52)-year age group
gave an additional benefit of around 3200 years of life for the
higher radiation risk assumption and 3500 for the lower respec-
tively (Figure 7). The lifetime cumulative risk of breast cancer due
to the radiation exposure increased from 9.29 to 9.31 for the lower
radiation risk level and to 9.37 for the higher respectively
(Table 1). The effect on cumulative reduction in breast cancer
mortality up to 100 years of age was around 16% (Table 1).
DISCUSSION
In this study we focused on the trade-off on breast cancer mortality
between avoided breast cancer deaths (due to earlier diagnosis)
and induced breast cancer deaths (due to ionizing radiation) asso-
ciated with different mammographic screening policies for a life-
long follow-up of a hypothetical cohort of 100 000 women.
There was a positive net effect in breast cancer mortality reduc-
tion for absorbed doses within reasonable limits for women
between 50 and 69 years of age at screening and using figures for
breast cancer mortality reductions as seen in the overview of the
Swedish randomized mammography screening trials (Nystrom
et al, 1993).
However, the main focus in this report was on mammographic
screening of women aged 40–49 years. Generally, even in this age
group the results indicate a net benefit in terms of years of life
gained and breast cancer deaths avoided. If the cumulative
absorbed breast dose is less than around 10 mGy and the annual
breast cancer mortality reduction is 25% (as in our first scenario),
the ratio between gained/lost years of life and avoided/induced
breast cancer deaths will exceed 10, independent of assumption of
the radiation risk. However, there are scenarios, not completely
unrealistic, that could give small net benefits or no benefit at all. In
the Swedish data on routine mammography the absorbed breast
dose per view was between 0.7 and 3.2 mGy at the various
screening centres (W Leitz, unpublished data). Furthermore, the
values for ERR Gy–1 in the cohort studies referred differ within a
factor of four (Mattsson et al, 1995). So, considering a screening
programme with annual, two-view examinations with an absorbed
dose per view of 3 mGy, giving a total dose of »50 mGy per
invited woman and assuming ERR Gy–1 to be the value observed
in the benign breast disease study (Mattsson et al, 1995), the net
benefit will be reduced considerably. If the reduction in annual
breast cancer mortality is less than 20% there is no net benefit for
avoided breast cancer deaths (Figures 4 and 5). It is also note-
worthy to point out that the number of radiation-induced cases in
this scenario is only contributing to a relatively small increase of
the cumulative incidence of breast cancer (0.2 percentage units for
a follow-up to 100 years of age).
This study has focused on the risk of radiation induced breast
cancer and this will influence the positive effect of screening in
terms such as gained years of life for a follow-up throughout life.
It is important that the follow-up is covering the whole lifetime,
because accessible data mainly reflects early positive effects
(10–15 years after screening start) whereas radiation-induced
breast cancer deaths are showing up after a considerably longer
period of time. With reasonable assumptions (such as in our
scenarios) the group 40–49 years of age will get a relatively large
benefit from mammographic screening in terms of years of life
gained or breast cancer deaths avoided.
A validation of mammographic screening programmes must
include also other factors like psychological effects and costs. In
normal circumstances the radiation risk is not crucial in the overall
assessment of the outcome of the programme. However, as shown
in this paper, the margins for women below age 50 are not very
large. When losing control over the radiation doses involved there
is a tangible risk that the net benefit will be reduced to a question-
able low value or even be turned into its opposite.
224 A Mattsson et al
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APPENDIX
Formulas
Subsections correspond to subsections in Material and Methods.
Total background breast cancer mortality
where
RB(I) = background risk of first primary breast cancer at
age I years.
LQ(I) = LQ(I21). [12Q(I21)]; size of population;
LQ(40) = 100 000.
Q(I) = death risks. From female population of Stockholm
1980–1989 (INREGIA).
SA (J2I) = cumulative survival rates of breast cancer patients.
DA (J2I) = annual death rates of breast cancer patients.
A = different survival and deaths rates for patients of
ages at diagnosis of breast cancer < 50 years,
50–69 years, and ³ 70 years.
Effects of mammographic screening
Reduction in background breast cancer mortality
where
E = age in years at first screening.
Z = number of years after first screening at age E years
the effect shows up.
EL = age at last screening.
P = annual relative reduction in breast cancer mortality.
If different reduction levels in breast cancer
mortality was assumed, e.g. for 40–49 years of age
and 50–69 years of age at screening, the third term
was separated in two parts accordingly.
LT = corresponds to a shift in incidence function
reflecting lead time. This shift was transferred to a
lower breast cancer mortality than otherwise. LT
was expected to be < 1 for 3 years after last
screening corresponding to mean lead time.
Thereafter LT =  1.
Radiation-induced breast cancer cases
where
Y = step in summation, corresponded to the time interval
between examinations.
BCM = S
100
I = 40
RB(I) · LQ(I) S
100
J = I
SA(J2I) · DA(J2I) (1)
RBCM = S
E–1
I=40S
100
J=40
BCM(I, J2I) + S
E+Z–
I=E
1
S
E+Z–
J=E
1
BCM(I, J2I) +
BCM(I,J–I)= RB(I) · LQ(I) · SA (J2I) · DA (J2I) from           (1).
(12P)S
EL
I=E S
100
J=E+Z
BCM(I, J21) + S
100
I=EL+1
LT(I) S
100
J=EL+1
BCM(I, J2I) (2)
N = S
EL
J=E,Y
ERRD(J)S
100
I=J
G(I2J) · RB(I) · LSP(I) (3)226 A Mattsson et al
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ERRD (J) = 0.69D · e–0.054D · e–0.06(J–40) [Benign breast disease
study (Mattsson et al, 1995)] or
ERRD (J) = 0.708D · e–0.0744(J–20) [Massachusetts fluoroscopy
study (Boice et al, 1991)].
G(I2J) = Graded impact of ERRD (J) I–J years after exposure
(NIH, 1985);
G(I2J<5) = 0;
G(5) = 0.074;
G(6) = 0.259;
G(7) = 0.50;
G(8) = 0.741;
G(9) = 0.926;
G(I2J>9) = 1.
LSP(I) = LSP (I21) [12QO (I21) +QBC (I21)  2RB (I21) 
2R N (I21)]
= size of the screened population.
LSP (40) = 100 000.
QO (I21) = overall deaths risk;
QBC (I21) = proportion of women that die from breast cancer;
added to avoid double counting.
RB (I21) = background risk of first primary breast cancer.
Women who have contracted breast cancer should
not be in question for routine screening and are
therefore subtracted.
RN (I21) = radiation induced risk of breast cancer
= N(I21)/LSP(I21). The corresponding cases were
subtracted with the same motivation as for RB.
Radiation-induced breast cancer deaths
• Assuming no effect of screening
This formula for the total number of induced breast cancer deaths
is analogous to formula (1):
where
N(I) = RB(I) · LSP(I)    S
min (EL,I)
J=E,Y
ERRD(J) · G(I2J) (5)
= total number of induced breast cancer cases
predicted to be diagnosed a specific year of attained
age. The summation over J gives the total ERR at a
specific attained age associated with the cumulative
exposure to ionizing radiation during the screening
programme.
• Assuming effect of mammographic screening (RIM) This
formula for the reduced number of radiation induced breast
cancer deaths is analogous to formula (2):
where
IM(I,J2I) = N(I) · SA (J2I) · DA (J2I) from                 (4).
Net effects
• Net total number of avoided breast cancer deaths
• Net number of gained years of life
where
YR(J) = expected number of remaining years of life at age J
years.
BCM(J) = appropriate summation over I for a given attained age
J years in formula 1.
RBCM (J)= appropriate summation over I for a given attained age
J years in formula 2.
RIM(J) = appropriate summation over I for a given attained age
J years in formula 6.
IM = S
100
I=E
N(I) S
100
J=I
SA (J–I) · DA (J2I) (4)
RIM = S
E+Z–
I=E
1
S
E+Z–
J=E
1
IM(I, J2I) + (12P) S
EL
I=E S
100
J=E+Z
IM(I, J2I) +
S
100
I=EL+1
LT(I) S
100
J=EL+1
IM(I, J2I) (6)
S
100
I=40
[BCM(J) 2 RBCM(J) + RIM(J)] (7)
S
100
I = 40
[{BCM(J) 2 RBCM(J) + RIM(J)}YR(J)]